Literature DB >> 9392421

Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism.

F C de Beer1, M C de Beer, D R van der Westhuyzen, L W Castellani, A J Lusis, M E Swanson, D S Grass.   

Abstract

Lipoprotein metabolism is markedly altered during inflammation. The concentration of human secretory phospholipase A2 (sPLA2) can increase hundreds of fold in inflammatory fluids and in the circulation. It was detected in atherosclerotic lesions where many inflammatory genes are induced. As sPLA2 has been reported to act on lipoproteins as substrates, lipoprotein profiles in transgenic mice expressing sPLA2 were studied. HDL levels were markedly decreased in transgenic mice overexpressing sPLA2. HDL in the transgenics were smaller in size, with a significant decrease (11%) in phospholipid content compared to nontransgenic littermates. In sPLA2 transgenic mice and transgenic mice expressing both sPLA2 and human apolipoprotein B (apoB), the concentrations of apoB-containing lipoproteins were not altered. We conclude that sPLA2 alters HDL metabolism and could be responsible for the depressed levels of HDL that exist during chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392421

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  12 in total

1.  Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity.

Authors:  Tomáš Vaisar; Chongren Tang; Ilona Babenko; Patrick Hutchins; Jake Wimberger; Anthony F Suffredini; Jay W Heinecke
Journal:  J Lipid Res       Date:  2015-05-20       Impact factor: 5.922

2.  ATP binding cassette G1-dependent cholesterol efflux during inflammation.

Authors:  Maria C de Beer; Ailing Ji; Anisa Jahangiri; Ashley M Vaughan; Frederick C de Beer; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2010-12-07       Impact factor: 5.922

3.  Impact of serum amyloid A on high density lipoprotein composition and levels.

Authors:  Maria C de Beer; Nancy R Webb; Joanne M Wroblewski; Victoria P Noffsinger; Debra L Rateri; Ailing Ji; Deneys R van der Westhuyzen; Frederick C de Beer
Journal:  J Lipid Res       Date:  2010-07-27       Impact factor: 5.922

4.  Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Authors:  Giorgio Cavigiolio; Shobini Jayaraman
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

5.  Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis.

Authors:  M S Kindy; A R King; J Yu; C Gerardot; J Whitley; F C de Beer
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

Review 6.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

7.  Increased hepatic cholesterol accumulation in transgenic mice overexpressing human secretory phospholipase A2 group IIA.

Authors:  Rolf Eckey; Mario Menschikowski; Peter Lattke; Werner Jaross
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

Review 8.  Role of secretory phospholipases in atherogenesis.

Authors:  Ann-Cathrine Jönsson-Rylander; Sofia Lundin; Birgitta Rosengren; Camilla Pettersson; Eva Hurt-Camejo
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

9.  HDL remodeling during the acute phase response.

Authors:  Anisa Jahangiri; Maria C de Beer; Victoria Noffsinger; Lisa R Tannock; Chandrashekar Ramaiah; Nancy R Webb; Deneys R van der Westhuyzen; Frederick C de Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-13       Impact factor: 8.311

Review 10.  The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

Authors:  Dimitar Divchev; Bernhard Schieffer
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.